Trials / Not Yet Recruiting
Not Yet RecruitingNCT05980208
A Real-world Study of Inetetamab for First-line Treatment of MBC
A Real-world Study of Inetetamab for First-line Treatment of HER2-positive Inoperable Locally Advanced or Relapsed Metastatic Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Hunan Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2 positive inoperable locally advanced or recurrent metastatic breast cancer. The research results will provide new targeted treatment strategies for HER2 positive breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inetetamab | Inetetamab-based treatment for first-line treatment of HER2-positive MBC |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2023-08-07
- Last updated
- 2023-08-08
Source: ClinicalTrials.gov record NCT05980208. Inclusion in this directory is not an endorsement.